INAB
IN8bio, Inc.
There isn't enough reported data to score INAB yet.
INAB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
INAB's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
INAB PE Valuation
INAB has no meaningful PE right now: it lost money over the past year.
INAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| High |
Analysts expect INAB's losses to shrink, with revenue holding steady.
INAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$22.20 | +$11.10 |
| Q2 2024 | -$24.60 | +$12.00 |
| Q1 2024 | -$27.00 | +$12.90 |
| Q4 2023 | -$30.00 | +$10.80 |
INAB is still losing money, but far less than before: $3.03 per share over the past year, against $46.96 at its worst in late 2021.
INAB Quarterly Revenue
INAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.9M | -$403K |
| Q2 2026 | -$3.7M | +$182K |
| Q1 2026 | -$4.9M | -$1.8M |
| Q4 2025 | -$2.1M | +$1.9M |
| Q3 2025 | -$3.5M | +$2.6M |
| Q2 2025 | -$3.9M | +$2.2M |
| Q1 2025 | -$3.1M | +$4.8M |
| Q4 2024 | -$4M | +$822K |
INAB has burned cash in almost every quarter: −$15M over the past year, against −$15M the year before.
INAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +6K shares |
| 1 year | +373% | +15.4M shares |
| 3 years | +2686% | +18.8M shares |
| 5 years | +2918% | +18.8M shares |
INAB has 19M diluted shares, up 373% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
INAB Net Leverage
INAB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
INAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.9 | Neutral |
| Stochastic | 9.2 | Oversold |
INAB's weekly RSI is 37 (neutral) and its Stochastic is 9 (oversold).
INAB PE vs Healthcare Sector
INAB has no meaningful PE right now: it lost money over the past year.
INAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.09 | 25% below |
| 20 week MA | $1.14 | 28% below |
| 50 week MA | $1.50 | 45% below |
| 100 week MA | $2.93 | 72% below |
| 200 week MA | $18.9 | 96% below |
INAB is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
INAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $300.0 | $184.5 | -39% |
| 2022 | $184.5 | $53.1 | -71% |
| 2023 | $53.1 | $41.4 | -22% |
| 2024 | $41.4 | $8.10 | -80% |
| 2025 | $8.10 | $2.23 | -72% |
| 2026 YTD | $2.23 | $0.82 | -63% |
INAB has finished every year since 2021 lower, and it's down 63% so far in 2026.